Blog

Company News

Industry Trends

Laws Regulations

All Categories >

04

2025-11

Application Showcase | Hycells One-Stop Comprehensive NK Cell Solution

Shanghai Hycells Biotechnology Co., Ltd. is a high-tech enterprise specializing in research on primary immune cells and stem cells. The company has established an integrated technology platform covering both immune cells and mesenchymal stem cells (MSCs), dedicated to providing customers with end-to-end cell-based solutions.

2025-11-04

He Yousheng

04

2025-11

Call for Papers | Application Process Now Open for 2025 SCI Paper Awards

On the journey of exploring life sciences, every breakthrough is worth celebrating, and every bit of support is worthy of gratitude. Hycells has consistently stood by your side, providing high-quality sample services, technical support, and specialized products to empower your research and development efforts. To express our heartfelt appreciation for the trust and support of both new and longstanding customers, Hycells is proudly launching a paper submission reward program—offering exclusive rewards as a token of our gratitude and paying tribute to every researcher!

2025-11-04

He Yousheng

20

2025-10

One-Stop Complete Solution for γδ T Cell Culture

As an emerging immunotherapy, γδ T-cell immunotherapy has become a new research hotspot due to its unique anti-tumor advantages. γδ T cells exert their anti-tumor effects primarily by secreting pro-apoptotic molecules and inflammatory cytokines, as well as through TCR-dependent mechanisms. Numerous clinical studies have demonstrated that γδ T-cell immunotherapy exhibits good tolerability and efficacy.

2025-10-20

He Yousheng

20

2025-10

Exhibition Invitation | The Inaugural Intelligent Technologies Forum for Drug Discovery and the WeMol User Conference

To mark the 10th anniversary of Weixin Computing, we cordially invite all WeMol platform users and drug discovery experts to gather in Shanghai for the inaugural Intelligent Technologies in Drug Discovery Forum and WeMol User Conference, to be held on November 8, 2025. With the theme “A New Paradigm for AI-Driven Drug Discovery: From Technology Leadership to Value Creation,” the event will feature presentations by numerous distinguished guests showcasing real-world user case studies, a focused exchange on cutting-edge applications of AI-assisted drug discovery, and an exploration of innovative R&D models that integrate computational and experimental approaches. Zhang Yingbo, Head of the Biotechnology Division at Shanghai Hycells, has also been invited to attend this conference.

2025-10-20

He Yousheng

20

2025-10

Exhibition Invitation | IGC2025: The 10th International Conference on Research, Development, and Industrialization of Cells and Derivatives

The 10th IGC 2025 Conference on Cell and Derivative R&D and Industrialization will be grandly inaugurated at the Langham Guangzhou on October 30–31. Leveraging the policy advantages of the Greater Bay Area, this year’s event features a plenary session and four specialized tracks, bringing together experts from more than 60 leading research institutions—including West China Lecity, Xiangxue, Baiji, Dabao, China Resources, Guanhao, Keyi, Beike, Sinovac, Laen, Tiankeya, Qianhui, Elp, Xidi, Ruizhen, Sipu, Ai Yi, and Aixiuma—as well as CEOs of industry-leading companies and partners from prominent investment firms, to jointly explore cutting-edge fields such as in vivo immune cell therapy, MSC/iPSC stem cell therapy, exosome-based therapies, and anti-aging medical aesthetics.

2025-10-20

He Yousheng

15

2025-09

Little “Sheng” Has a Reason Learning Hall | TDCC Experimental Skills Intensive Training Course

With the rapid advancement of cancer immunotherapy, novel therapeutic modalities such as bispecific antibodies, immune cell engagers, and adoptive cell therapies have emerged one after another. A core mechanism underlying these approaches is the redirection and activation of T cells to achieve specific cytotoxicity against tumor cells. The T cell–dependent cellular cytotoxicity (TDCC) assay, regarded as the “gold standard” for in vitro efficacy assessment of such agents, plays a pivotal role in drug screening, mechanistic studies, and preclinical evaluation.

2025-09-15

He Yousheng
< 1...345...15 >